Status Awaiting development
Technology type Medicine
Decision None selected
Process STA Standard
ID number 1136

Email enquiries


Companies sponsors Bristol-Myers Squibb
Others Department of Health
  NHS England
  NHS Knowsley CCG
  NHS St Helens CCG
  Welsh Government
Patient carer groups Beating Bowel Cancer
  Black Health Agency
  Bladder and Bowel Community
  Bowel Cancer Information
  Bowel Cancer UK
  Cancer Black Care
  Cancer Equality
  Colostomy Association
  Helen Rollason Cancer Charity
  IA: lleostomy and Internal Pouch Support Group
  Independent Cancer Patients Voice
  Lynch Syndrome UK
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Coloproctology of Great Britain and Ireland
  British Geriatrics Society
  British Institute for Radiology
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  Cancer Research UK
  Pelican Cancer Foundation
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (irinotecan, fluorouracil, oxaliplatin)
  Actavis UK (capecitabine, irinotecan, oxaliplatin)
  Almirall (fluorouracil)
  Hospira UK (irinotecan, folinic acid, fluorouracil, oxaliplatin, raltitrexed)
  Meda Pharmaceuticals (fluorouracil)
  Medac (folinic acid, fluorouracil, oxaliplatin)
  Pfizer (irinotecan)
  Roche (capecitabine)
  Seacross pharmaceuticals (irinotecan)
  Servier Laboratories (trifludine-tipiracil)
  Sun Pharmaceutical Industries Ltd (oxaliplatin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bowel & Cancer Research
  Cochrane Colorectal Cancer Group
  CORE (Digestive Disorders Foundation)
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
30 November 2023 Please note that following on from advice received from the company this appraisal has been rescheduled. We now anticipate that the appraisal will begin during late-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late-June 2024.
03 August 2023 Awaiting development. Please note that following on from information received from the company, this appraisal has now been scheduled back into the work programme. The timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-March 2024 when we will write to you about how you can get involved.
31 January 2018 Suspended. The company have notified the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that it wishes to withdraw its application for a marketing authorisation for nivolumab for this indication. The NICE appraisal of nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] will therefore be suspended.
16 November 2017 Committee meeting: 1
26 June 2017 In progress. Appraisal has started
23 June 2017 Invitation to participate
23 March 2017 - 13 April 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
02 March 2017 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual